{"id":5771,"date":"2024-09-09T07:26:50","date_gmt":"2024-09-09T12:26:50","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5771"},"modified":"2025-06-27T08:38:43","modified_gmt":"2025-06-27T13:38:43","slug":"nanoscope-therapeutics-announces-presentations-at-the-retina-society-and-advanced-therapies-europe-annual-meetings-in-lisbon","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2024\/09\/09\/nanoscope-therapeutics-announces-presentations-at-the-retina-society-and-advanced-therapies-europe-annual-meetings-in-lisbon\/","title":{"rendered":"Nanoscope Therapeutics anuncia presentaciones en las reuniones anuales de la Retina Society y Advanced Therapies Europe en Lisboa"},"content":{"rendered":"<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<p><span class=\"legendSpanClass\" style=\"font-size: revert; color: #888888;\"><span class=\"xn-location\">DALLAS<\/span><\/span><span style=\"font-size: revert; color: #888888;\">,\u00a0<\/span><span class=\"legendSpanClass\" style=\"font-size: revert; color: #888888;\"><span class=\"xn-chron\">9 de septiembre de 2024<\/span><\/span><span style=\"font-size: revert; color: #888888;\">\u00a0 \u2014 <\/span><a style=\"font-size: revert;\" href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4249323-1&h=1622630530&u=https%3A%2F%2Fnanostherapeutics.com%2F&a=Nanoscope+Therapeutics+Inc.\" target=\"_blank\" rel=\"nofollow noopener\">Nanoscopio Therapeutics Inc.<\/a><span style=\"font-size: revert; color: #888888;\">, una empresa de biotecnolog\u00eda en etapa cl\u00ednica que desarrolla terapias gen\u00e9ticas para enfermedades hereditarias de la retina, anunci\u00f3 hoy presentaciones en el\u00a0<\/span><a style=\"font-size: revert;\" href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4249323-1&h=2835900256&u=https%3A%2F%2Fwww.retinasociety.org%2Fpage%2F2%2Fannual-meetings&a=Retina+Society+57th%C2%A0Annual+Scientific+Meeting\" target=\"_blank\" rel=\"nofollow noopener\">Sociedad de retina 57<sup>th<\/sup>\u00a0Reuni\u00f3n Cient\u00edfica Anual<\/a><span style=\"font-size: revert; color: #888888;\">\u00a0y en\u00a0<\/span><a style=\"font-size: revert;\" href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4249323-1&h=526419003&u=https%3A%2F%2Fadvancedtherapieseurope.phacilitate.com%2F&a=Advanced+Therapies+Europe\" target=\"_blank\" rel=\"nofollow noopener\">Terapias Avanzadas Europa<\/a><span style=\"font-size: revert; color: #888888;\">\u00a0teniendo lugar durante el 2<\/span><sup style=\"color: #888888;\">Dakota del Norte<\/sup><span style=\"font-size: revert; color: #888888;\">\u00a0semana de septiembre en\u00a0<\/span><span class=\"xn-location\" style=\"font-size: revert; color: #888888;\">Lisboa, Portugal<\/span><span style=\"font-size: revert; color: #888888;\">. Los detalles de las presentaciones son los siguientes:<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<article class=\"news-release inline-gallery-template\">\n<section class=\"release-body container\">\n<div class=\"row\">\n<div class=\"col-lg-10 col-lg-offset-1\">\n<p><b>T\u00edtulo:<\/b>\u00a0An\u00e1lisis de la agudeza visual corregida (MAVC) de pacientes tratados con terapia optogen\u00e9tica agn\u00f3stica de la mutaci\u00f3n MCO-010 en dosis baja o alta para la retinitis pigmentosa: resultados TOPLINE de 100 semanas de un estudio de fase\u00a0<span class=\"xn-money\">2b<\/span>\/3 Ensayo cl\u00ednico aleatorizado y controlado con placebo (RESTORE)<br class=\"dnr\" \/><b>T\u00edtulo de la sesi\u00f3n:\u00a0<\/b><a href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4249323-1&h=910328593&u=https%3A%2F%2Fwww.retinasociety.org%2Fcontent%2Fdocuments%2Fpreliminary-program-subject-to-change.pdf&a=Genetic+Diseases%2C+Dystrophies+%26+Degenerations\" target=\"_blank\" rel=\"nofollow noopener\">Enfermedades gen\u00e9ticas, distrofias y degeneraciones<\/a><br class=\"dnr\" \/><b>Fecha de la sesi\u00f3n:\u00a0<\/b><span class=\"xn-chron\">11 de septiembre de 2024<\/span><br class=\"dnr\" \/><b>Tiempo de sesi\u00f3n:\u00a0<\/b><span class=\"xn-chron\">16:25<\/span>\u00a0OESTE<br class=\"dnr\" \/><b>Ubicaci\u00f3n:\u00a0<\/b>Sal\u00f3n Pedro Leitao, Four Seasons Hotel Ritz,\u00a0<span class=\"xn-location\">Lisboa<\/span><br class=\"dnr\" \/><b>Presentador:\u00a0<\/b><span class=\"xn-person\">Anat L\u00f6wenstein<\/span>, MD, MHA, Profesor y Director, Divisi\u00f3n de Oftalmolog\u00eda,\u00a0<span class=\"xn-org\">Universidad de Tel Aviv<\/span><\/p>\n<p>En su presentaci\u00f3n, la Dra. Loewenstein destacar\u00e1 los datos del final del estudio RESTORE de 100 semanas de la terapia con opsina multicaracter\u00edstica (MCO) independiente de la mutaci\u00f3n para la p\u00e9rdida grave de la visi\u00f3n debido a la retinitis pigmentosa.<\/p>\n<p><b>T\u00edtulo:<\/b>\u00a0Democratizar la terapia g\u00e9nica para enfermedades neurodegenerativas<br class=\"dnr\" \/><b>T\u00edtulo de la sesi\u00f3n:<\/b>\u00a0 Terapia g\u00e9nica: avances y avances destacados<br class=\"dnr\" \/><b>Fecha de la sesi\u00f3n:<\/b>\u00a0<span class=\"xn-chron\">11 de septiembre de 2024<\/span><br class=\"dnr\" \/><b>Tiempo de sesi\u00f3n:<\/b>\u00a04:15 pm OESTE<br class=\"dnr\" \/><b>Ubicaci\u00f3n:<\/b>\u00a0Centro de Convenciones de Estoril,\u00a0<span class=\"xn-location\">Lisboa<\/span><br class=\"dnr\" \/><b>Presentador:<\/b>\u00a0Samarendra Mohanty, PhD, Presidente y Director Cient\u00edfico<\/p>\n<p>Durante su presentaci\u00f3n, el Dr. Mohanty destacar\u00e1 los recientes avances y desarrollos en la terapia g\u00e9nica optogen\u00e9tica independiente de la mutaci\u00f3n para la restauraci\u00f3n de la visi\u00f3n en distrofias retinianas hereditarias, y la plataforma de administraci\u00f3n de genes l\u00e1ser dirigida espacialmente y guiada por im\u00e1genes para el tratamiento de la atrofia geogr\u00e1fica. La presentaci\u00f3n ser\u00e1 seguida por un panel de discusi\u00f3n en\u00a0<span class=\"xn-chron\">16:45<\/span>El Dr. Mohanty tambi\u00e9n presidir\u00e1 una sesi\u00f3n titulada<b>\u00a0\u201c<\/b>\u201dFlexibilidad en acci\u00f3n: aprovechamiento de plataformas de vectores adaptativos para la fabricaci\u00f3n de terapias g\u00e9nicas\u201d, el 12 de septiembre de 2024, de 13:45 a 15:00 (hora del oeste).<br class=\"dnr\" \/><br class=\"dnr\" \/><\/p>\n<p><b>Acerca de Nanoscope Therapeutics Inc.<br class=\"dnr\" \/><\/b>Nanoscope Therapeutics est\u00e1 desarrollando terapias optogen\u00e9ticas que restauran la vista y son independientes de los genes para los millones de pacientes cegados por enfermedades degenerativas de la retina, para las cuales no existe cura. El activo principal de la compa\u00f1\u00eda, MCO-010, inform\u00f3 recientemente los resultados principales del ensayo cl\u00ednico RESTORE Fase 2b, multic\u00e9ntrico, aleatorizado, de doble enmascaramiento y controlado de forma simulada en los EE. UU. para la retinosis pigmentaria (<a href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4249323-1&h=3079635195&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3939588-1%26h%3D1414634841%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3823946-1%2526h%253D153867349%2526u%253Dhttps%25253A%25252F%25252Fclinicaltrials.gov%25252Fct2%25252Fshow%25252FNCT04945772%25253Fterm%25253DNanoscope%252526draw%25253D2%2526a%253DNCT04945772%26a%3DNCT04945772&a=NCT04945772\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a>). La empresa tambi\u00e9n ha completado el ensayo de fase 2 STARLIGHT de la terapia MCO-010 en pacientes con Stargardt (<a href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4249323-1&h=3797683388&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3939588-1%26h%3D1223114861%26u%3Dhttps%253A%252F%252Fclinicaltrials.gov%252Fct2%252Fshow%252FNCT05417126%26a%3DNCT05417126&a=NCT05417126\" target=\"_blank\" rel=\"nofollow noopener\">NCT05417126<\/a>). MCO-010 ha recibido designaciones de v\u00eda r\u00e1pida de la FDA y designaciones de medicamento hu\u00e9rfano de la FDA tanto para RP como para Stargardt. Los activos precl\u00ednicos incluyen la terapia g\u00e9nica MCO-020 administrada con l\u00e1ser no viral para la atrofia geogr\u00e1fica.<\/p>\n<p><b>Contacto de inversores:<\/b><br class=\"dnr\" \/>Socios Argot<br class=\"dnr\" \/>(212) 600-1902<br class=\"dnr\" \/><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a><\/p>\n<\/div>\n<\/div>\n<\/section>\n<\/article>","protected":false},"excerpt":{"rendered":"<p>DALLAS,\u00a0Sept. 9, 2024\u00a0 \u2014 Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, today announced presentations at the\u00a0Retina Society 57th\u00a0Annual Scientific Meeting\u00a0and at\u00a0Advanced Therapies Europe\u00a0taking place during the 2nd\u00a0week of September in\u00a0Lisbon, Portugal. Details for the presentations are as follows: Title:\u00a0BCVA Analysis of Patients Treated with Low- or High-Dose MCO-010 [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":5772,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5771","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics Announces Presentations at the Retina Society and Advanced Therapies Europe Annual Meetings in Lisbon - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2024\/09\/09\/nanoscope-therapeutics-announces-presentations-at-the-retina-society-and-advanced-therapies-europe-annual-meetings-in-lisbon\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Announces Presentations at the Retina Society and Advanced Therapies Europe Annual Meetings in Lisbon - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2024\/09\/09\/nanoscope-therapeutics-announces-presentations-at-the-retina-society-and-advanced-therapies-europe-annual-meetings-in-lisbon\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2024-09-09T12:26:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-27T13:38:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_LI_RetinaSociety24_Loewenstein_V1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"1200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_LI_RetinaSociety24_Loewenstein_V1.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/09\\\/nanoscope-therapeutics-announces-presentations-at-the-retina-society-and-advanced-therapies-europe-annual-meetings-in-lisbon\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/09\\\/nanoscope-therapeutics-announces-presentations-at-the-retina-society-and-advanced-therapies-europe-annual-meetings-in-lisbon\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics Announces Presentations at the Retina Society and Advanced Therapies Europe Annual Meetings in Lisbon\",\"datePublished\":\"2024-09-09T12:26:50+00:00\",\"dateModified\":\"2025-06-27T13:38:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/09\\\/nanoscope-therapeutics-announces-presentations-at-the-retina-society-and-advanced-therapies-europe-annual-meetings-in-lisbon\\\/\"},\"wordCount\":382,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/09\\\/nanoscope-therapeutics-announces-presentations-at-the-retina-society-and-advanced-therapies-europe-annual-meetings-in-lisbon\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/NSCOPE_LI_RetinaSociety24_Loewenstein_V1.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/09\\\/nanoscope-therapeutics-announces-presentations-at-the-retina-society-and-advanced-therapies-europe-annual-meetings-in-lisbon\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/09\\\/nanoscope-therapeutics-announces-presentations-at-the-retina-society-and-advanced-therapies-europe-annual-meetings-in-lisbon\\\/\",\"name\":\"Nanoscope Therapeutics Announces Presentations at the Retina Society and Advanced Therapies Europe Annual Meetings in Lisbon - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/09\\\/nanoscope-therapeutics-announces-presentations-at-the-retina-society-and-advanced-therapies-europe-annual-meetings-in-lisbon\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/09\\\/nanoscope-therapeutics-announces-presentations-at-the-retina-society-and-advanced-therapies-europe-annual-meetings-in-lisbon\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/NSCOPE_LI_RetinaSociety24_Loewenstein_V1.jpg\",\"datePublished\":\"2024-09-09T12:26:50+00:00\",\"dateModified\":\"2025-06-27T13:38:43+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/09\\\/nanoscope-therapeutics-announces-presentations-at-the-retina-society-and-advanced-therapies-europe-annual-meetings-in-lisbon\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/09\\\/nanoscope-therapeutics-announces-presentations-at-the-retina-society-and-advanced-therapies-europe-annual-meetings-in-lisbon\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/09\\\/nanoscope-therapeutics-announces-presentations-at-the-retina-society-and-advanced-therapies-europe-annual-meetings-in-lisbon\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/NSCOPE_LI_RetinaSociety24_Loewenstein_V1.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/NSCOPE_LI_RetinaSociety24_Loewenstein_V1.jpg\",\"width\":1200,\"height\":1200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/09\\\/nanoscope-therapeutics-announces-presentations-at-the-retina-society-and-advanced-therapies-europe-annual-meetings-in-lisbon\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Announces Presentations at the Retina Society and Advanced Therapies Europe Annual Meetings in Lisbon\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics anuncia presentaciones en las reuniones anuales de la Retina Society y Advanced Therapies Europe en Lisboa - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2024\/09\/09\/nanoscope-therapeutics-announces-presentations-at-the-retina-society-and-advanced-therapies-europe-annual-meetings-in-lisbon\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics Announces Presentations at the Retina Society and Advanced Therapies Europe Annual Meetings in Lisbon - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2024\/09\/09\/nanoscope-therapeutics-announces-presentations-at-the-retina-society-and-advanced-therapies-europe-annual-meetings-in-lisbon\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2024-09-09T12:26:50+00:00","article_modified_time":"2025-06-27T13:38:43+00:00","og_image":[{"width":1200,"height":1200,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_LI_RetinaSociety24_Loewenstein_V1.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_LI_RetinaSociety24_Loewenstein_V1.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2024\/09\/09\/nanoscope-therapeutics-announces-presentations-at-the-retina-society-and-advanced-therapies-europe-annual-meetings-in-lisbon\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2024\/09\/09\/nanoscope-therapeutics-announces-presentations-at-the-retina-society-and-advanced-therapies-europe-annual-meetings-in-lisbon\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics Announces Presentations at the Retina Society and Advanced Therapies Europe Annual Meetings in Lisbon","datePublished":"2024-09-09T12:26:50+00:00","dateModified":"2025-06-27T13:38:43+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/09\/09\/nanoscope-therapeutics-announces-presentations-at-the-retina-society-and-advanced-therapies-europe-annual-meetings-in-lisbon\/"},"wordCount":382,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/09\/09\/nanoscope-therapeutics-announces-presentations-at-the-retina-society-and-advanced-therapies-europe-annual-meetings-in-lisbon\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_LI_RetinaSociety24_Loewenstein_V1.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2024\/09\/09\/nanoscope-therapeutics-announces-presentations-at-the-retina-society-and-advanced-therapies-europe-annual-meetings-in-lisbon\/","url":"https:\/\/nanostherapeutics.com\/2024\/09\/09\/nanoscope-therapeutics-announces-presentations-at-the-retina-society-and-advanced-therapies-europe-annual-meetings-in-lisbon\/","name":"Nanoscope Therapeutics anuncia presentaciones en las reuniones anuales de la Retina Society y Advanced Therapies Europe en Lisboa - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/09\/09\/nanoscope-therapeutics-announces-presentations-at-the-retina-society-and-advanced-therapies-europe-annual-meetings-in-lisbon\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/09\/09\/nanoscope-therapeutics-announces-presentations-at-the-retina-society-and-advanced-therapies-europe-annual-meetings-in-lisbon\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_LI_RetinaSociety24_Loewenstein_V1.jpg","datePublished":"2024-09-09T12:26:50+00:00","dateModified":"2025-06-27T13:38:43+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2024\/09\/09\/nanoscope-therapeutics-announces-presentations-at-the-retina-society-and-advanced-therapies-europe-annual-meetings-in-lisbon\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2024\/09\/09\/nanoscope-therapeutics-announces-presentations-at-the-retina-society-and-advanced-therapies-europe-annual-meetings-in-lisbon\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2024\/09\/09\/nanoscope-therapeutics-announces-presentations-at-the-retina-society-and-advanced-therapies-europe-annual-meetings-in-lisbon\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_LI_RetinaSociety24_Loewenstein_V1.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_LI_RetinaSociety24_Loewenstein_V1.jpg","width":1200,"height":1200},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2024\/09\/09\/nanoscope-therapeutics-announces-presentations-at-the-retina-society-and-advanced-therapies-europe-annual-meetings-in-lisbon\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Announces Presentations at the Retina Society and Advanced Therapies Europe Annual Meetings in Lisbon"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5771","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=5771"}],"version-history":[{"count":3,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5771\/revisions"}],"predecessor-version":[{"id":9020,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5771\/revisions\/9020"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/5772"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=5771"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=5771"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=5771"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}